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Context. Cancer patients receiving high doses of opioids as background
medication are challenging, and it would be useful clinically to know whether
a rapid-onset opioid (ROO) for breakthrough cancer pain (BTcP) may be started
at a dose proportional to the background opioid dose.
Objectives. The aim of this study was to assess the efficacy and safety of the
fentanyl buccal tablet (FBT) in doses proportional to the opioid dose
administered for background analgesia in a sample of patients with BTcP who
were receiving high doses of opioids.
Methods. Twelve patients who were receiving opioids for background analgesia
at doses equivalent to more than 500 mg of oral morphine and had adequately
controlled pain were prospectively recruited. BTcP was treated with proportional
doses of FBT: patients receiving 600 mg of oral morphine equivalents were
administered 1000 mg of FBT, patients receiving 900 mg of oral morphine
equivalents were administered 1500 mg of FBT, and so on. For each episode of
BTcP, trained nurses collected pain intensity (on a 0e10 numerical rating scale)
and emerging problems when called for increases in pain considered to be severe
in intensity by patients (T0) and 15 minutes after FBT administration (T15).
Results. Patients were receiving mean doses of oral morphine equivalents of
1340 mg (585; range 720e2400). Seventy-nine events were treated with FBT
(6.6 4.9 for each patient). The median pain intensity of BTcP events was 8
(range 7e10), and the mean dose of FBT administered was 2233 mg (975; range
1200e4000). In most events, a decrease in pain intensity >33% and >50% was
observed (n¼ 14 and n¼ 48, respectively) 15 minutes after the administration ofAddress correspondence to: SebastianoMercadante, MD,
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Vol. 42 No. 3 September 2011 465Fentanyl Buccal Tablets and Dose ProportionsFBT. Data on 11 episodes were missed. Only six events were unsuccessfully treated.
In all the patients, the level of adverse effects after FBT administration was mild
and indistinguishable from that associated with the background opioid analgesia.
Conclusion. FBT in doses proportional to the high doses of opioids used for
background analgesia was efficacious andwell tolerated when administered for BTcP.
Controlled studies with a specific design and a large number of patients should
confirm such preliminary results. J Pain Symptom Manage 2011;42:464e469.
 2011 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.Key Words
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In the cancer population, breakthrough can-
cer pain (BTcP) is a transitory exacerbation of
pain superimposed on an otherwise stable
pain pattern in patients treated with opioids.1
BTcP is normally severe in intensity and has
a rapid onset. The presence of BTcP has been
considered as a negative prognostic factor for
adequate pain control and interferes with the
quality of life of these patients.2 The availability
of supplemental doses of opioids in addition to
the continuous analgesicmedication is themain
treatment suggested to manage these pain
flares, either during dose titration or whenbasal
pain is under control. The use of rapid-onset
opioids (ROOs) has been shown to provide
pain relief that occurs more quickly than that
achieved with an orally administered drug.3
The opioid dose to be administered for
BTcP is controversial. All the trials with
ROOs, including oral transmucosal fentanyl
citrate (OTFC) and the fentanyl buccal tablet
(FBT), suggest a lack of relationship between
the effective the fentanyl dose and a fixed-
schedule opioid regimen, regardless of the
opioid used.3 However, in these studies, a sub-
stantial proportion of patients failed dose titra-
tion of OTFC or FBT,4 and observations from
data pooled from trials of OTFC showed
a statistically significant relationship between
the breakthrough dose and around-the-clock
dose, despite enormous interindividual vari-
ability in patients’ dose requirements for
BTcP.5 Moreover, an unclear distinction be-
tween the basal pain of mild-moderate inten-
sity and BTcP of moderate-severe intensity
makes the interpretation of data provided by
these studies difficult. The use of proportional
doses has been shown to be promptly effectivewithout producing relevant adverse effects in
an acute palliative care unit setting.6e9 A pre-
dictable dose may favor an easy prescription,
resulting in better patient compliance.
The findings of these studies suggest that
patients receiving opioids for chronic cancer
pain may not sustain more risk from the
administration of a ROO dose that is propor-
tional to the basal opioid regimen, especially
if the background opioid dose is relatively
high. This can be explained by the protective
effect offered by opioid tolerance in patients
chronically receiving relevant opioid doses
for the management of cancer pain.
It would be useful clinically to know whether
a ROOmay be started at a dose proportional to
the background opioid dose. If the ROO is initi-
ated at too low adose, in an attempt to titrate the
doses individually, this could result in unneces-
sary suffering, lowered clinical compliance, and
refusal to continue the treatment. Patients re-
ceiving high doses of opioids as background
medication are challenging and have never
been the subject of clinical studies. The aim of
this study was to prospectively assess the efficacy
and safety of FBT in doses proportional to opi-
oid doses for background analgesia given
chronically for the treatment of BTcP in cancer
patients receiving high doses of opioids.Patients and Methods
Patients receiving opioids at doses equivalent
to more than 500 mg of oral morphine as back-
ground analgesia and having pain under con-
trol for most daily hours (pain intensity #4/10
on a numerical scale of 0e10) were prospec-
tively recruited for this study for a period of
eight months. Other medications, including
466 Vol. 42 No. 3 September 2011Mercadante et al.symptomatic drugs or coanalgesics, when indi-
cated,were added toopioids tomaintaina stable
analgesia with limited adverse effects. Patients
with relevant coexisting liver or renal disease
(double values of normal ranges in creatinine,
bilirubin, orhepatic enzymes), cognitive impair-
ment, an expected survival of less than one
month, requiring radiotherapy, or starting
a new course of chemotherapy were excluded.
Informed consent and approval by the local
ethics committee were obtained.
BTcP was treated with proportional doses of
FBT, according to local policy.9 For example,
patients receiving 600 mg of oral morphine
equivalents were administered 1000 mg of FBT,
patients receiving 900 mg of oral morphine
equivalents were administered 1500 mg of FBT,
and so on. Tablets were placed between the
upper gum and cheek, above and/or below
the molar tooth on each side, or on both sides,
according to the number of tablets needed to
administer the calculated doses.
Patients were treated according to the de-
partment policy, that is, patients were encour-
aged to call when their pain became severe
($7 on a numerical scale from 0 to 10). For
each episode, trained nurses collected changes
in pain intensity (on a numerical scale 0e10)
and emerging problems when called for pain
increases considered to be severe in intensity
by patients (T0) and 15 minutes after FBT
administration (T15). Daily doses of opioids
administered for basal analgesia also were re-
corded. As a routine, a physician on duty is
present in the department and the palliative
care team is available on call for any emer-
gency or consultation.
Patients were offered intravenous morphine
(about one-fifth of the daily oral dose converted
to the intravenous route) if they were not satis-
fied with the treatment by T15, according to
department policy and previous experience.6,7
Thenumber of patients who reported a decrease
in pain intensity of >33% and >50% was re-
corded 15 minutes after the administration of
FBT. Episodes with less than a 33% reduction
in pain or requiring further treatment were con-
sidered unsuccessful.
Statistical Analysis
Data were collected and analyzed by the SPSS
software version 14.0 (SPSS, Inc., Chicago, IL).
Statistical analysis of quantitative andqualitativedata, including descriptive statistics, was per-
formed for all the items. Bivariate correlations
using nonparametric (Spearman’s coefficient)
correlation analysis were calculated for the asso-
ciation of FBT doses and decrease in pain inten-
sity <33%, >33%, and >50%.Results
From January to August 2010, 12 patients re-
ceiving strong opioids in doses higher than
500 mg/day of oral morphine equivalents were
recruited. The mean age was 58.9 (SD 11.6)
years. In total, 79 BTcP events were treated
with FBT (mean 6.6 4.9 for each patient).
Patients’ characteristics are listed in Table 1.
All patients had their background pain under
control (pain intensity of 4/10 or less on a nu-
merical scale 0e10) and were receiving mean
doses equivalent to oral morphine 1340 mg
(585; range 720e2400). Five patients were
receiving pregabalin (Patients 1, 2, 3, and 12)
or duloxetine (Patient 6).
On a 0e10 numeric rating scale, the median
pain intensity of BTcP events was 8 (range
7e10). The mean doses of FBT administered
were 2233 mg (975; range 1200e4000). In
most events, a decrease in pain intensity
>33% and >50% was observed (n¼ 14 and
n¼ 48, respectively), 15 minutes after the ad-
ministration of FBT. Data on 11 episodes
were missed. Only six events were unsuccess-
fully treated (decrease of pain intensity 15 min-
utes after FBT administration of less than
33%). There was no correlation between the
FBT doses used and the reduction in pain in-
tensity (>33%, Spearman’s correlation coeffi-
cient: 0.026, P¼ 0.926; >50%, Spearman’s
correlation coefficient: 0.132, P¼ 0.423; <33%,
Spearman’s correlation coefficient: 0.286, P ¼
0.260). In all cases, adverse effects after FBT
administration weremild and undistinguishable
from those associated with basal opioid analge-
sia, independent of the dose administered.Discussion
The aim of this study was to assess efficacy
and safety of ROOs commonly used for the
treatment of BTcP in patients who were receiv-
ing high doses of opioids for background
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Vol. 42 No. 3 September 2011 467Fentanyl Buccal Tablets and Dose Proportionsanalgesia. Among the ROOs available for the
management of BTcP, FBTwas chosen because
of its good bioavailability, which yields less
dose-to-dose variability than OTFC.10
The opioid dose to be administered for
BTcP is controversial. All the trials with
OTFC and FBT suggest a lack of relationship
between the effective fentanyl dose and
a fixed-schedule opioid regimen, regardless
of the opioid used.3 This finding has suggested
the need to begin therapy at a low dose and
titrate to higher doses in every case. To affirm
that this is the optimal clinical paradigm, these
titration methods should be compared with
proportional doses in terms of efficacy and
safety, but such studies have not been per-
formed so far.4 Moreover, in the studies that
have demonstrated a lack of proportionality,
a substantial number of patients failed dose
titration, eliminating the chance to clarify
the extent of proportionality within the
larger opioid-treated population. Interestingly,
observations from data pooled from trials of
OTFC showed a statistically significant rela-
tionship between the breakthrough dose and
around-the-clock dose, despite an enormous
interindividual variability in patients’ dose
requirements for BTcP.5
The use of proportional doses has been
shown to be safe and effective when using
OTFC and intravenous morphine, even in pa-
tients receiving relatively high doses of opioids
for their background pain, and only a minority
of patients required further treatment.6e9 The
proportional doses used in these studies were
effective and safe, and no patient needed inter-
vention for adverse effects. The use of a dose
that is proportional to the background opioid
dose may protect patients from failed titration
or periods of suffering before achieving the ap-
propriate individualized dose (a time period
that could, in certain cases, require weeks, as
determined in the controlled studies).
This is the first study assessing the use of high
doses of FBT for BTcP, as data on doses higher
than 800 mg of FBT have never been pub-
lished.11,12 In all previous experiences with
FBT, patients who did not obtain satisfactory an-
algesia with 800 mg discontinued the study.13 A
pharmacokinetic study has shown that higher
doses of FBT produce a proportional increase
in plasma concentration.14 As a consequence,
further analgesia can be expected when doses
468 Vol. 42 No. 3 September 2011Mercadante et al.are escalated inpatientswhoarehighly tolerant,
such as those receiving high doses of strong opi-
oids for background analgesia.
FBT in doses proportional to oral opioids
given for background analgesia was safe and
effective in this series of patients, reproducing
the same effects reported in patients receiving
lower doses, but after dose titration.11,15 Most
patients obtained a relevant decrease in pain
intensity within 15 minutes, more than 50%
in more than 60% of events. Of interest, and
in contrast to previous controlled studies of
opioid titration, the selection of BTcP events
included in this survey may allow a better inter-
pretation of data because the intensity of BTcP
(at least 7/10) was clearly distinguished
from the intensity of basal pain (no more
than 4/10). This means that the confounding
influence of the gray area of mild pain for
either background analgesia or BTcP often
reported in these studies, which may interfere
with the quality of the data collected and their
interpretation, was limited. Similarly, the cut-
off in selecting the events successfully treated
was more restrictive (at least a 33% decrease
in pain intensity). Despite the uncontrolled
nature of the study design, the most strict
selection of the BTcP events to be treated
offers a clinical outcome reproducible in daily
practice. The treatment was safe and effective,
and only a minority of patients had an insuffi-
cient response. Drugs were given by trained
nurses autonomously evaluating BTcP and fol-
lowing the prescription ordered on the clinical
sheet, which incorporated the proportional
dosing.
Although a certain dose is necessary to cover
most BTcP events with severe intensity, the
pains may have different presentations and un-
predictable courses. It could be argued that
this approach could expose patients to adverse
effects. However, no patient required a medical
intervention, including older patients who
could potentially be at risk, regardless of the
type of opioid, dose, route, and age. This
observation confirms that opioid tolerance,
produced by relative high opioid doses used
for background analgesia, is a protective factor
against the occurrence of severe adverse
effects. Preliminary and confirmatory surveys
have shown the safety of this approach in
a large number of patients; no life-
threatening adverse effects occurred, even inolder patients. Respiratory depression, which
is the most feared adverse effect, has never oc-
curred, and no emergency call was needed.6e9
In a recent survey reproducing a real clinical
scenario, patients receiving a mean oral mor-
phine dose of 132 mg required 800 mg of OTFC
after dose titration,16 suggesting that the titra-
tion process may reveal a need for even higher
doses that those expected by using proportional
dosing. Similarly, in a recent long-term study of
FBT, themeandose of FBTwas 554 mg inpatients
who were receiving mean doses of 240 mg/day
oral morphine equivalents as background anal-
gesia, and approximately half of the patients
used the maximum FBT dose of 800 mg during
maintenance treatment.12 These mean doses of
FBT (554 mg) were consistently higher than
those eventually calculated with a proportional
approach (400 mg for mean doses of 240 mg of
oral morphine equivalents as around-the-clock
analgesia), confirming that overdosing with pro-
portional doses calculated according to the opi-
oid basal regimen is unlikely. These patients,
however, needed titration, with evident suffering
during the days before achieving the right dose.
In conclusion, FBT in doses proportional to
the high doses of opioids used for background
analgesia was effective as breakthrough pain
medication. This approach did not produce
relevant adverse effects. However, these data
should be considered with caution, given the
preliminary nature of this study. The limited
observations in a selected population do not
allow broad conclusions of any type, including
those focused on safety, particularly given the
general concerns about the approach to pro-
portionate dosing of ROOs. Moreover, data
were collected in an acute pain relief and pal-
liative care unit offering strict monitoring and
should not be extended to other contexts.
Controlled studies with a specific design with
a large number of patients should be per-
formed to confirm such preliminary results.References
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